Biosimilars industry stakeholders will finally be able to see the effect of a US interchangeability designation on a product in the marketplace, after Viatris and Biocon launched their Semglee (insulin glargine-yfgn) and unbranded Insulin Glargine biosimilars in the US.
“Both biosimilar products are available in vial and pre-filled pen presentations and are interchangeable for the reference brand, Lantus, allowing for